Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H15ClN6O |
Molecular Weight | 318.761 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C)C(CN2C=NC3=C2N=C(N)N=C3Cl)=NC=C1C
InChI
InChIKey=QULDDKSCVCJTPV-UHFFFAOYSA-N
InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)
Molecular Formula | C14H15ClN6O |
Molecular Weight | 318.761 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
BIIB021 binds in the ATP-binding pocket of Hsp90, interferes with Hsp90 chaperone function, and results in client protein degradation and tumor growth inhibition. Hsp90 is overexpressed in many types of cancer and acts to stabilize malignancy producing oncoproteins. Therefore, inhibition of Hsp90 with BIIB021 leads to the degradation of oncoproteins that drive malignancy.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07900 Gene ID: 3320.0 Gene Symbol: HSP90AA1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28443462 |
1.7 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1439 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22898035 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIIB021 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2942 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22898035 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
BIIB021 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24097863/ |
600 mg 2 times / week multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BIIB021 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. | 2007 Jun 14 |
|
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. | 2009 Apr |
|
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. | 2009 Aug 15 |
|
An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. | 2010 Feb |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01004081
In a phase II clinical trial, breast cancer patients were treated with either 100 mg twice daily + exemestane 25 mg once per day for 28 days, or 450 mg three times weekly + exemestane 25 mg once per day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24241349
BIIB021 was investigated as an inhibitor of heat shock protein 90 (Hsp90) alone and in combination with triptolide (TPL) on T-cell acute lymphoblastic leukemia. The cell viability of Human T-ALL cell line Molt-4 was measured using MTT assay. Molt-4 cells were treated with BIIB021 (50-800 nmol/L) which inhibited the cell growth in a dose-dependent manner. The IC50 value was 384.6 and 301.8 nmol/L, respectively, at 48 and 72 h.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:43 GMT 2025
by
admin
on
Mon Mar 31 18:04:43 GMT 2025
|
Record UNII |
851B9FQ7Q0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
848695-25-0
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
90687
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
DTXSID601025952
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
300000041484
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
DB12359
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
851B9FQ7Q0
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
16736529
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY | |||
|
C62517
Created by
admin on Mon Mar 31 18:04:43 GMT 2025 , Edited by admin on Mon Mar 31 18:04:43 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|